Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Editas Medicine

10X Genomics

CRISPR is an acronym which refers to a series of DNA sequences in bacteria and other organisms. Scientists have begun editing genes, including CRISPR,  to try to improve human health.

3 CRISPR Stocks to Buy Now Or You'll Be Kicking Yourself Later

Beam Therapeutics

Cellectis SA

Intellia Therapeutics

Sangamo Therapeutics

Verve Therapeutics

CRISPR technology has the potential to revolutionize the way we approach medicine. This technology has already been used in a variety of applications, including gene editing, gene therapy, and disease diagnosis.

7 CRISPR Stocks With the Best Long-Term Potential

AbbVie

To many investors, gene editing sounds like the plot of a science fiction movie. The concept of being able to edit our DNA to cure genetic diseases is quite unbelievable, and the upside of gene editing to treat rare diseases is impressive.

3 Gene Editing Stocks to Buy Now OR You'll Be Kicking Yourself Later

Global X Genomics & Biotechnology ETF

Gene editing stocks present themselves as one of the more lucrative investments in the healthcare sector. Gene editing, a revolutionary take on the science of genetic engineering, has the potential to countless lives around the globe.

3 Gene Editing Stocks With the Best Long-Term Potential

bluebird bio

Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.

Better Biotech Buy: Bluebird Bio or CRISPR Therapeutics?

ARK Innovation ETF

Coinbase

DraftKings

Exact Sciences

Invitae

Pacific Biosciences of California

Roblox

Roku

Cathie Wood's ARK Innovation ETF is back — and back big. It's the top diversified ETF again this year so far, largely due to big winners.

Cathie Wood Is Crushing It This Year Thanks To 9 Stocks

CureVac B.V

Exelixis

Incyte

Pfizer

Sarepta Therapeutics

If you have the patience to go through wild undulations, then you may be a candidate for biotech stocks that will make you rich in 10 years. Even among the most established biotechnology firms, they're seemingly one news item away from disaster.

7 Biotech Stocks That Will Make You Rich in 10 Years

CRISPR could revolutionize the way we treat thousands of diseases.  Many of these diseases occur when mutations affect genes, or when people have the wrong amount of genetic material,  the Cleveland Clinic reported.

3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years

Intuitive Surgical

These companies are set for a new era of growth.

2 Stocks Down More Than 25% to Buy Right Now

Amazon

Home Depot

Moderna

Starbucks

These stocks all dropped in the double digits last year. But their future prospects are brilliant.

5 Potentially Explosive Stocks to Buy in 2023

Inmode Ltd

These two companies are in very different situations but could generate significant returns for investors.

More Likely to 5X First: CRISPR Therapeutics vs. InMode

Prime Medicine Inc

CRISPR Therapeutics is probably the most widely-known company utilizing the original CRISPR-Cas9 gene editing method. Prime editing is a newer variation on CRISPR-Cas9 which is safer since it doesn't produce double-strand breaks in DNA.

Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics

Shopify

At their beaten-down valuations, these stocks have the potential to deliver some impressive returns.

2 Growth Stocks You May Regret not Buying Right Now

ZUG, Switzerland and CAMBRIDGE, Mass., Jan. 11, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to participate in B. Riley Securities' 3rd Annual Oncology Conference on Wednesday, January 18, 2023, at 10:30 a.m. ET.

CRISPR Therapeutics to Participate in B. Riley Securities' 3rd Annual Oncology Conference

Vertex Pharmaceuticals

Both are hoping to use the latest gene editing technology to make the lucrative therapies of tomorrow.

2 Risky Cathie Wood Stocks to Buy Today And Hold For 5 Years

AbCellera Biologics

AST SpaceMobile

JFrog

HashiCorp

Maxar Technologies

MongoDB

UiPath

Planet Labs

Rocket Lab USA

Sumo Logic

Tesla

While others flock to safety, should you do the opposite? Some of the best times to invest in highly speculative names are when no one wants them, as long as the reasons are macro and not company or industry specific.

10 Potential 10x Return Stocks For The Next 10 Years

CRISPR Therapeutics AG is a gene editing company based on CRISPR/Cas9 technology. CRISPR method seems to be the preferred in Gene Editing.

CRISPR Therapeutics: 2023 Could Be The Right Year

PayPal

These stocks fell significantly in 2022. But analysts expect that huge rebounds could be on the way in the new year.

3 Growth Stocks That Could Skyrocket 50% or More In 2023, According to Wall Street

Teladoc

Both stocks have fallen brutally this year, but only one has a chance to recover soon.

1 Cathie Wood Stock to Buy While It's Affordable, and 1 to Avoid (for Now)

Biogen

Pharma and biotech stocks are enjoying tailwinds as part of the broad market rally today.

3 Biotech Stocks to Watch Heading Into 2023

The gene-editing stock still has plenty of promise.

Could CRISPR Therapeutics Help You Become a Millionaire?

Crispr expects to make history in 2023 with a first-ever request in gene-editing technology by the same name, which could stoke shares. The post Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?

Crispr Stock In 2023: Will Down-In-The-Dumps Shares Sparkle Again In 2023?

These businesses aren't in as much trouble as their stock returns suggest that they are.

3 Cathie Wood Stocks That Could Make Big Comebacks in 2023

ZUG, Switzerland and BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced the appointment of Alex Harding, M.D., M.B.A., as Senior Vice President and Head of Business Development, effective January 5, 2023. Dr. Harding brings extensive leadership experience in biopharma business development and corporate strategy and joins CRISPR Therapeutics to lead the Company's business development operations.

CRISPR Therapeutics Announces the Appointment of Alex Harding, M.D., M.B.A., as Head of Business Development

Zoetis

These stocks could have significant upside opportunities ahead.

3 Beaten-Down Stocks That Could Explode Higher in 2023

News for CRISPR Therapeutics Stock (CRSP)